期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 25, 期 12, 页码 1373-1383出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543776.2015.1093113
关键词
bone; cancer; hypercalcemia; inflammation; neuronal diseases; nuclear receptors; prodrugs; selective modulators
资金
- Nihon University School of Medicine
- Japan Society for the Promotion of Science (JSPS) under KAKENHI [25460394]
- Grants-in-Aid for Scientific Research [25460394] Funding Source: KAKEN
Introduction: The vitamin D receptor (VDR) is a promising drug target in the treatment of cancer, autoimmune disease, inflammation, infection and cardiovascular disease, as well as bone and mineral disorders. Although many VDR ligands have been developed and shown to activate VDR in vitro and in vivo, including vitamin D derivatives and non-secosteroidal compounds, a principal adverse effect of hypercalcemia has limited their clinical application.Areas covered: We summarize recent patent activity regarding VDR ligands, including vitamin D derivatives, non-secosteroidal compounds and tissue-selective prodrugs, alongside their therapeutic applications. The potential for use of VDR ligands in the treatment of hepatic fibrosis, pancreatic fibrosis and neuronal disease is also reviewed.Expert opinion: Several VDR ligands have been shown to have increased therapeutic efficiency in experimental models of cancer, inflammation and cardiovascular disease, and to exhibit function-selective and/or tissue-selective activity. The underlying molecular and pharmacological mechanisms remain to be elucidated. Further studies, both basic and applied, should make successful VDR-targeting therapy possible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据